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The purpose of this phase II trial was to assess the efficacy and toxicity of paclitaxel
and nedaplatin (TN) as the initial postoperative adjuvant chemotherapy for uterine
cervical cancer with lymph node metastases (LNM). Patients with FIGO stage IB1-
IIA2 squamous cell carcinoma of the uterine cervix were enrolled. Histological con-
firmation of LNM was mandatory. Intravenous paclitaxel at 175 mg/m2 and neda-
platin at 80 mg/m2 were administered every 28-day cycle, of which there were
5 cycles after radical hysterectomy. Sixty-two patients were enrolled in the study
from November 2011 to July 2015. Their median age was 48.5 years (range 28-64).
The median tumor diameter was 37 mm (5-64). Overall, 30 patients (48.4%) had 1
metastatic lymph node, 11 (17.7%) had 2, 3 (4.8%) had 3, 5 (8.1%) had 4, and 13
(21.0%) had 5 or more. With a median follow-up of 45.7 months (range 23.4-69.5),
the 2-year relapse-free survival and 2-year overall survival rates were 79.0% (90%
CI, 69.0%-86.2%) and 93.5% (95% CI, 83.7%-97.5%), respectively. Almost all adverse
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events were relatively mild. Grade 3-4 adverse events (NCI-CTC ver. 4.0) that
occurred in 5% or more of patients were neutropenia (60.7%) and infection (6.6%).
The proportion of patients who completed 5 cycles of treatment was 90.3%. Post-
operative adjuvant chemotherapy with TN for cervical cancer with LNM was
demonstrated to be an effective and feasible treatment. A phase III trial is war-
ranted to compare this with concurrent chemoradiotherapy.
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1 | INTRODUCTION
Cervical cancer is the most common gynecological malignancy world-
wide, accounting for 7.9% (57 600) of new cancer cases and 7.5%
(265 700) of all cancer deaths among females in 2012.1 The inci-
dence of cervical cancer is higher in developing countries because of
the lower availability of cancer screening systems. In developed
countries, the majority of cervical cancer patients are diagnosed at
an early stage of the disease (FIGO stages I-II).
Patients with early-stage cervical cancer require radical hysterec-
tomy with pelvic lymphadenectomy or definitive radiotherapy (RT)/
concurrent chemoradiotherapy (CCRT). In Japan, at more than 80%
of institutions, radical hysterectomy is chosen as the primary treat-
ment for patients with stage IB1 and IIA1 tumors.2 Subsequently,
patients with prognostic risk factors for recurrence receive postoper-
ative adjuvant therapy. Peters et al.3 showed a significant survival
advantage associated with the use of CCRT rather than RT alone in
patients with high-risk cervical cancer. In the guidelines for cervical
cancer of several countries, the pathological findings of lymph node
metastasis (LNM) and/or parametrial invasion (PMI) are defined as
high-risk prognostic factors, and postoperative CCRT is recom-
mended as adjuvant treatment for these cases.4-8
There has recently been much debate regarding the risk-benefit
balance of postoperative CCRT for cervical cancer.9-12 Patients with
LNM have been shown to exhibit a greater rate of distant failure
than those without this,9,10 so postoperative adjuvant therapy should
not only control local recurrence, but also prevent distant metastasis.
Postoperative CCRT would be expected to induce serious toxicities,
which could continue throughout the patient’s life; this is because
the organ in the pelvis targeted by RT has already been subjected to
radical surgery.11,12 In this context, systemic chemotherapy (CT)
alone could play an important role as postoperative adjuvant therapy
for patients with high-risk cervical cancer.
The combination of paclitaxel plus platinum is standard treatment
for patients with advanced/recurrent cervical cancer.13,14 Nedaplatin
(cis-diammine glycolato platinum) was developed as a less nephro-
toxic and neurotoxic analog of cisplatin. We showed that the combi-
nation of paclitaxel plus nedaplatin (TN) would have favorable
antitumor activity and be feasible for advanced/recurrent cervical
cancer.15 Recently, Li et al.16 showed the efficacy of nanoparticle
albumin-bound paclitaxel plus nedaplatin for patients with advanced/
recurrent cervical cancer.
We conducted a phase II trial involving the application of post-
operative systemic CT alone with the combination of paclitaxel plus
nedaplatin to uterine cervical cancer patients with LNM, to evaluate
the efficacy and toxicity of this regimen.
2 | MATERIALS AND METHODS
All patients provided written informed consent before enrollment.
The trial was registered with the UMIN-Clinical Trials Registry
(UMIN000005605) and was conducted in accordance with the Dec-
laration of Helsinki. The trial protocol was approved by the Kansai
Clinical Oncology Group (KCOG) Protocol Review Committee and
the institutional review board of each participating institution before
patient enrollment.
2.1 | Eligibility
Patients who had undergone radical hysterectomy and pelvic lym-
phadenectomy for FIGO stage IB1, IB2 or IIA of uterine cervix
were enrolled in this trial. Histological type included squamous cell
carcinoma alone. Histological confirmation of LNM was mandatory.
In addition, patients had to have: no residual tumor after surgery;
age ranging from 20 to 70; and ECOG performance status score
0-1. Patients were also required to have adequate hematological
(absolute neutrophil count [ANC] ≥1500/lL, platelets ≥100 000/
lL, hemoglobin ≥9.0 g/dL), renal (creatinine ≤1.5 mg/dL) and hep-
atic function (bilirubin ≤1.2 mg/dL, sGOT/GPT ≤100 U/L). Patients
were excluded from the study if they had para-aortic LNM con-
firmed histologically, a positive surgical margin or peritoneal
metastasis.
2.2 | Treatment
Treatment had to be started within 6 weeks after surgery. Che-
motherapy administration was as follows: paclitaxel at 175 mg/m2
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over 3 hour plus nedaplatin at 80 mg/m2 over 1 hour on day 1.
Five cycles of chemotherapy were repeated every 28 days.
Patients were premedicated with dexamethasone (20 mg) and rani-
tidine (50 mg) or famotidine (20 mg) intravenously 30-90 minute
prior to infusion. Diphenhydramine (50 mg) was also given orally
30 minute prior to treatment. Chemotherapy was discontinued in
cases of progressive disease, unacceptable toxicity or patient’s
refusal.
All patients were required to have an ANC of more than
1500/lL and a platelet count more than 75 000/lL prior to
beginning each cycle. They were removed from the study if their
blood count had not recovered by 3 weeks after treatment. Dose
modifications were made to paclitaxel or nedaplatin for hemato-
logical, gastrointestinal, hepatic or neurologic toxicity, based on
the most severe grade of toxicity, using the National Cancer Insti-
tute-Common Toxicity Criteria (NCI-CTC) version 4.0. Dose reduc-
tion levels of paclitaxel/nedaplatin were 150/70 mg/m2 (level 1),
135/60 mg/m2 (level 2) and 110/50 mg/m2 (level 3). Patients
requiring dose reduction to less than level 3 were removed from
the study.
2.3 | Follow-up evaluation
Prior to each cycle of treatment, a physical examination, routine
hematologic studies and blood chemistry analysis were conducted.
Once protocol treatment had ended, the patients were evaluated by
pelvic examination, Papanicolaou tests, and an analysis of serum
squamous cell carcinoma antigen level at the discretion of the
attending physician every 1-3 months in the first 2 years, and every
4-6 months during years 3, 4 and 5. In addition, patients underwent
a CT or MRI scan every 6 months in the first 2 years and annually
thereafter until 5 years.
2.4 | Statistical methods
The sample size was initially calculated based on the assumption
of an expected 2-year relapse-free survival (RFS) rate of 80% and
the threshold value of 65%, which was based on previously pub-
lished data.15-18 Under these assumptions, 58 patients were
required to achieve a 1-sided significance level of 5% with power
of 85%. Factoring in a 5% dropout rate, we set a target sample
size of 63 patients. The primary endpoint of the current study
was 2-year RFS, defined as the interval between the date of entry
into the study and the date of the first physical or radiographic
evidence of disease recurrence. The secondary endpoints were
overall survival (OS), adverse events and rate of completion of
protocol treatment. OS was calculated from the date of entry into
the study to the date of death or last follow-up visit. RFS and
OS were calculated using the Kaplan-Meier method, and their
confidence intervals (CI) were estimated by Greenwood’s formula.
All statistical analyses were performed using SAS 9.4 (SAS Insti-
tute, Cary, NC, USA).
3 | RESULTS
3.1 | Patient characteristics
Sixty-two patients were enrolled from 14 institutions between
November 2011 and July 2015. All patients were eligible for this
study, so data from 62 patients were included in the analysis. The
baseline characteristics of the patients are shown in Table 1. Their
median age was 48.5 years (range 28-64). Fifty-five patients (88.7%)
had a performance status (PS) of 0, while 6 patients (9.7%) had a PS
of 1. Median tumor diameter was 37 mm (5-64). Overall, 10 patients
(16.1%) had parametrial invasion, 44 (71.0%) had deep stromal inva-
sion and 53 (85.5%) had lymphovascular invasion. The median num-
ber of resected lymph nodes was 41 (13-88). In total, 30 patients
(48.4%) had 1 metastatic lymph node, 11 (17.7%) had 2, 3 (4.8%)
had 3, 5 (8.1%) had 4, and 13 (21.0%) had 5 or more.
3.2 | Feasibility
Fifty-six patients (90.3%) completed the treatment protocol as
planned. Of the 6 patients who did not complete it, 2 experienced
disease progression, 1 prolonged neutropenia, 1 severe allergic reac-
tion for nedaplatin, 1 vesical perforation that resulted from late mor-
bidity of radical hysterectomy, and 1 refused the treatment. Three
TABLE 1 Patient characteristics (N = 62)
N (%)
Age Median 48.5 (Range 28-64)
Performance status
0 55 (88.7)
1 6 (9.7)
Unknown 1 (1.6)
FIGO stage
IB1 22 (35.5)
IB2 23 (37.1)
IIA 17 (27.4)
Tumor diameter, mm Median 37 (Range 5-64)
Number of dissected lymph nodes Median 41 (Range 13-88)
Number of metastatic lymph nodes
1 30 (48.4)
2 11 (17.7)
3 3 (4.8)
4 5 (8.1)
5 or more 13 (21.0)
Parametrial invasion, yes 10 (16.1)
Deep stromal invasion, yes 44 (71.0)
Lymphovascular invasion, yes 53 (85.5)
Vaginal invasion, yes 20 (32.3)
Positive surgical margin, yes 0 (0)
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patients (4.8%) needed dose reduction up to level 1. Among the
total of 292 cycles administered, treatment delay occurred in 25 cy-
cles (8.6%).
3.3 | Adverse events
The adverse events are summarized in Table 2. Thirty-seven patients
(60.7%) had grade 3-4 neutropenia, while 1 (1.6%) had grade 3-4
anemia. Febrile neutropenia occurred in 1 patient alone (1.6%).
There was no severe thrombocytopenia. With regard to non-hema-
tological toxicities, the most common adverse event was alopecia (all
grades, 95.0%). Sensory neuropathy (all grades, 81.7%), myalgia/
arthralgia (all grades, 66.7%) and fatigue (all grades, 55.7%) were also
common, but there were no grade 3-4 non-hematological adverse
events in 5% or more of the patients.
Whether the number of dissected lymph nodes was associated
with toxicity in all grades was evaluated. Neutropenia was more
common in patients with ≥40 dissected lymph nodes than in those
with <40 (87.5% vs 65.5%, P = .041); in contrast, thrombocytopenia
was rarer in patients with 40 or more dissected lymph nodes than in
those with <40 (0% vs 13.8%, P = .030). The other toxicities had no
significant difference between the 2 groups.
3.4 | Survival analysis
The median follow-up duration was 45.7 months (range 23.4-69.5).
Follow-up data from all patients were available. Data regarding
recurrence and death are shown in Table 3. Among 15 patients with
recurrence, 9 patients had locoregional recurrence, 5 had distant
recurrence, and 1 had both. All 7 deaths were caused by deteriora-
tion of the disease.
Table 4 shows the actual clinical courses of the 15 patients with
recurrence. Of 9 patients with locoregional recurrence, 8 were trea-
ted with RT or CCRT as salvage therapy and, among them, 3 pa-
tients are alive with no evaluable disease and 1 is alive with disease.
Among 5 patients with distant recurrence, 3 patients with para-aor-
tic recurrence were treated with RT or CCRT, and 1 patient with
liver metastasis underwent surgery as salvage therapy. Among these
5 patients, 3 patients are alive without disease. A total of 53
patients (85.5%) are alive without disease, 2 (3.2%) are alive with
disease and 7 (11.3%) have died of disease. The 2-year RFS, 2-year
OS and estimated 4-year OS rates were 79.0% (90% CI, 69.0%-
86.2%), 93.5% (83.7%-97.5%) and 87.1% (74.5%-93.7%), respectively
(Figure 1A,B).
4 | DISCUSSION
We report the positive results of a phase II trial involving the appli-
cation of postoperative systemic CT alone to uterine cervical cancer
patients with lymph node metastases. Adjuvant CT alone with TN
after radical hysterectomy was demonstrated to be an effective and
feasible treatment.
In the current phase II study, the 2-year RFS, 2-year OS and esti-
mated 4-year OS rates were 79.0%, 93.5% and 87.1%, respectively,
which were comparable to those seen in previous reports of adju-
vant CCRT for the patients with high-risk factors;3,17,18 nevertheless,
the patients in the current study would have more severe risk fac-
tors than those in most previous studies. All patients in the current
study had LNM, among which approximately 30% had 2-3 metas-
tases, approximately 20% had 5 or more metastases, and approxi-
mately 20% had common iliac lymph node metastases. Peters et al.3
showed that the estimated 4-year PFS and OS rates for patients
receiving CCRT were 80% and 81% in a phase III trial in which
TABLE 2 The reported acute toxicities
Toxicities
N (%)
Any grade G3/4
Hematological toxicities
Neutropenia 47 (77.0) 37 (60.7)
Anemia 26 (42.6) 1 (1.6)
Thrombocytopenia 4 (6.6) 0
Febrile neutropenia 1 (1.6) 1 (1.6)
Non-hematological toxicities
Blood bilirubin increased 2 (3.3) 0
Liver enzyme increased 16 (26.2) 0
Creatinine increased 4 (6.6) 0
Hyperkalemia 4 (6.6) 0
Infection 8 (13.1) 4 (6.6)
Allergy 5 (8.2) 1 (1.6)
Vasculitis 7 (11.5) 0
Anorexia 32 (53.3) 1 (1.6)
Nausea 38 (63.3) 1 (1.6)
Vomiting 6 (10.0) 1 (1.6)
Diarrhea 9 (15.0) 0
Constipation 29 (47.5) 0
Pharyngitis/stomatitis 4 (6.7) 0
Alopecia 57 (95.0) (grade 2≧) 43 (71.7)
Rash/exanthema 18 (30.0) 1 (1.6)
Edema 11 (18.3) 0
Fatigue 34 (55.7) 1 (1.6)
Sensory neuropathy 49 (81.7) 0
Motor neuropathy 3 (5.0) 0
Myalgia/arthralgia 40 (66.7) 1 (1.6)
TABLE 3 Recurrence and death (N = 15)
Site N (%)
Recurrence 15 (24.2)
Locoregional 9 (14.5)
Distant 5 (8.1)
Both 1 (1.6)
Death 7 (11.3)
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approximately 90% of patients had nodal involvement and 3% had
common iliac nodal involvement. Sehouli et al.17 showed that the 2-
year PFS was 81.8% and the estimated 5-year OS was 77.4% for
patients receiving CCRT. In the study by Sehouli et al., only half of
the patients had nodal involvement.
Adjuvant chemotherapy alone with TN after radical hysterectomy
was demonstrated to be safe and feasible. In the current study,
90.3% of patients completed the treatment protocol as planned and
grade 3-4 gastrointestinal toxicities occurred in only 1 patient. There
has recently been much debate regarding the risk-benefit balance of
postoperative CCRT for cervical cancer.9-12 Postoperative CCRT
would be expected to induce serious gastrointestinal toxicity, which
could continue throughout the patient’s life; this is because the
organ in the pelvis that would be targeted by RT has already been
subjected to radical surgery.11,12 Takekuma et al.11,12 report that the
level of invasiveness of the surgical procedure might be associated
with the toxicities of adjuvant CCRT, which meant that patients with
≥40 dissected lymph nodes had significantly more non-hematological
toxicities of adjuvant CCRT than those with <40. They suggested
that, for patients undergoing CCRT, the use of this radical surgery to
increase the possibility of a permanent cure has to be balanced
against the possibility of developing a serious illness in association
with the postoperative therapy. In this context, systemic CT alone
could play an important role as postoperative adjuvant therapy for
patients with high-risk cervical cancer.12 In the current study, the
rates of severe non-hematological toxicity were only 0%-6.6%
(Table 2). The evaluation of whether the number of dissected lymph
nodes was associated with toxicity in all grades showed that there
were significant differences regarding neutropenia and thrombocy-
topenia between patients with ≥40 dissected lymph nodes and those
with <40, the reason for which was unclear. However, non-hemato-
logical toxicities did not differ significantly between the 2 groups.
These findings suggest that postoperative TN therapy could be
undergone safely regardless of the level of invasiveness of the surgi-
cal procedure.
In the current study, no severe neurotoxicity or thrombocytope-
nia occurred, which matched the results of a previous phase II study
revealing the efficacy of TN therapy for advanced/recurrent cervical
cancer.15 Currently, paclitaxel combined with carboplatin (TC) is
accepted as one of the standard treatment options for cervical can-
cer, in accordance with the results of the JCOG0505 trial, showing
the noninferiority of TC to paclitaxel and cisplatin.14 Severe neuro-
toxicity occurred in 4.8% and severe thrombocytopenia occurred in
24.6% of patients of the TC arm in the JCOG0505 trial, indicating
TABLE 4 Clinical course of patients with recurrence (N = 15)
Site of recurrence
Salvage
therapy Status
Locoregional recurrence
Vaginal RTa Alive
Vaginal CCRTb Alive
Vaginal CCRT Alive
Vaginal CCRT AWDc
Vaginal RT Dead
Vaginal RT Dead
Intra-pelvic lymph nodes CCRT Dead
Intra-pelvic lymph nodes CTd Dead
Peritoneum in pelvis RT Dead
Distant recurrence
Para-aortic lymph nodes CCRT Alive
Para-aortic lymph nodes CCRT Alive
Para-aortic lymph nodes RT Dead
Liver Surgery Alive
Lung and mediastinal lymph nodes CT Dead
Both
Intra-pelvic, para-aortic, and mediastinal lymph
nodes
CT AWD
CCRT, concurrent chemoradiotherapy; RT, radiotherapy.
aRadiotherapy alone.
bConcurrent chemoradiotherapy.
cAlive with disease.
dSystemic chemotherapy alone.
F IGURE 1 Outcomes of eligible patients enrolled in the KCOG-G1101 study. A, 2-year relapse-free survival: 79.0% (90% CI, 69.0%-86.2%).
B, 2-year overall survival: 93.5% (83.7%-97.5%)
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that these toxicities remain unresolved. A TN therapy could be an
alternative to a regimen of postoperative adjuvant CT.
The most beneficial aspect of using systemic CT alone in a post-
operative setting is that RT could be utilized for recurrences in the
pelvis as salvage therapy if the pelvic field has not yet been irradi-
ated. In the current study, 8 patients with recurrence in the pelvis
and 3 patients with para-aortic recurrence were treated with RT or
CCRT as salvage therapy; 6 of these are still alive and would be
expected to survive for a long time. Another particularly beneficial
aspect of systemic CT alone would be that systemic CT could con-
trol distant metastasis. The Gynecologic Oncology Group (GOG) in
the USA has conducted a randomized phase III trial, the GOG0724
trial (NCT00980954), to test the hypothesis that the addition of fur-
ther cycles of systemic CT following the completion of CCRT would
decrease distant metastasis and improve survival. In contrast, there
might be a discouraging aspect of using systemic CT alone associ-
ated with local control. In the current study, more intra-pelvic recur-
rence occurred (16.1%) than in the CCRT arm of Peters’ trial (8.7%).3
It has been proposed that systemic CT alone could have a sur-
vival benefit even without RT. Several retrospective studies on post-
operative adjuvant CT alone have also been reported and all of them
conclude that systemic CT alone as postoperative adjuvant therapy
could obtain similar or better results compared with RT/CCRT.18-21
Matsuo et al.22 showed in a multi-institutional retrospective study
that systemic chemotherapy might be as effective a postoperative
treatment as radiation-based therapy in node-positive stage IB-IIB
cervical cancer. In a phase III trial conducted by Curtin et al.,
patients were randomized to systemic CT alone and systemic CT fol-
lowed by whole pelvic RT after radical hysterectomy. Although this
trial could not achieve a positive result regarding the primary end-
point, they conclude that the patterns of recurrence were statisti-
cally similar between the 2 arms, and both regimens were well
tolerated.23
The current study has a few limitations. First, the follow-up per-
iod was short. The expected survival duration of the patients in the
current study would be relatively long because this is a study on
early-stage disease. A secondary endpoint in the current study is the
5-year OS, for which the results will be reported at a later date. Sec-
ond, the late adverse events could not be reported. The standard
postoperative adjuvant therapy is RT or CCRT in which severe late
adverse events have occurred, and so compared with this standard
treatment, data of the late adverse event of CT alone would be
important. Third, in the current study, no restrictions were placed on
the surgical procedure performed; namely, radical hysterectomy or
lymphadenectomy. The results of postoperative adjuvant therapy
could be affected by the outcome of the surgery performed before
the study.
In summary, adjuvant CT alone with TN after radical hysterec-
tomy for patients with high-risk early-stage cervical cancer was
demonstrated to be an effective and feasible treatment. We suggest
that a prospective randomized study be conducted with the aim of
testing the noninferiority of systemic CT alone to CCRT as optimal
adjuvant therapy for patients with factors placing them at high risk
for recurrence.
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